EGG

UnknownPhase NA

Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study

Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study (EGG Study)

Lead sponsor

Sengkang General Hospital

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI 27.5-34.9

Primary endpoint

•Total body weight loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05569304

Org study IDCIRB Ref: 2022/2469

Timeline

Milestones

Study first posted2022-10-06actual

Last update posted2022-10-06actual

Study start2022-10-07estimated

Primary completion2025-12-31estimated

Study completion2025-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age21 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients with classes 1 (BMI 27.5 to 34.9) and 2 (BMI 35 to 39.9) obesity in accordance with the World Health Organisation recommendations but modified to the interventional thresholds recommended for Asian populations

Exclusion criteria

•Patients with class 3 obesity and above (BMI > 40.0)

•Patients with contraindications to GLP-1 analogues

•Patients with contraindications to endoscopic sleeve gastroplasty

•Patients with previous bariatric or upper gastrointestinal surgery

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other (unclassified)

Weight & body composition

4 endpoints

Primary/protocol endpoint

Total body weight loss

Time frame:1-year

descriptive

Secondary/protocol endpoint

Short-term weight loss

Time frame:3-months

descriptive

Secondary/protocol endpoint

Short-term weight loss

Time frame:6-months

descriptive

Secondary/protocol endpoint

Short-term weight loss

Time frame:9-months

descriptive

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Healthcare costs

Time frame:1-year

descriptive

Secondary/protocol endpoint/low confidence

Metabolic outcomes

Time frame:3-months, 6-months, 9-months, 12-months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.